Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

This study is testing whether adding the targeted drug afatinib to chemotherapy can shrink non-small cell lung cancer (NSCLC) tumors enough to make surgery possible in patients who were initially told their cancer couldn't be removed. **You may be eligible if...** - You have been diagnosed with Stage III non-small cell lung cancer that cannot be surgically removed - Your tumor has a specific genetic change called an EGFR sensitive mutation (found by a tissue or blood test) - You are in good general health (able to carry out daily activities) - You have not received prior chemotherapy or radiation for this lung cancer **You may NOT be eligible if...** - Your cancer is a mixed type (e.g., combines small cell and non-small cell) - You have fluid around the lungs caused by cancer - You have uncontrolled bowel conditions like Crohn's disease or severe diarrhea Talk to your doctor to see if this trial is right for you.